Related Experiment Video
Updated: Aug 13, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Pharmacogenomics of acute leukemia
Meyling H Cheok1, Sanne Lugthart, William E Evans
1St. Jude Children's Research Hospital, Department of Pharmaceutical Sciences, Memphis, TN 38105, USA. meyling.cheok@stjude.org
Annual Review of Pharmacology and Toxicology
|January 13, 2006
Summary
Pharmacogenomics offers personalized treatment strategies for childhood leukemia, aiming to improve cure rates and reduce relapses. This approach enhances drug efficacy and patient safety by considering individual genetic profiles.
Area of Science:
- Pediatric Oncology
- Pharmacogenomics
- Cancer Genetics
Background:
- Childhood leukemia treatment has advanced significantly, with cure rates reaching 80% for acute lymphoblastic leukemia and 45% for acute myeloid leukemia.
- Despite progress, leukemia relapse remains a significant challenge in pediatric oncology.
- Optimizing existing treatments, rather than new drug discovery, has driven recent therapeutic gains.
Purpose of the Study:
- To review recent pharmacogenomic studies in pediatric acute leukemia treatment.
- To highlight the potential of pharmacogenomics in personalizing cancer therapy.
- To establish childhood leukemia as a model for pharmacogenomic advancements in cancer treatment.
Main Methods:
- Review of candidate-gene association studies.
- Analysis of genome-wide association studies (GWAS) including haplotype mapping.
- Examination of gene expression profiling in relation to treatment outcomes.
Main Results:
- Pharmacogenomic studies are identifying genetic factors influencing treatment response and toxicity in pediatric leukemia.
- Candidate-gene and genome-wide approaches reveal potential biomarkers for personalized therapy.
- Gene expression profiling offers insights into individual patient variability.
Conclusions:
- Pharmacogenomics holds significant promise for advancing pediatric acute leukemia treatment.
- Personalized medicine strategies based on genetic makeup can enhance treatment efficacy and safety.
- Childhood leukemia serves as a crucial paradigm for the application of pharmacogenomics in broader cancer treatment.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...